XML 51 R36.htm IDEA: XBRL DOCUMENT
v3.5.0.2

Note 2 - Acquisitions (Details Textual) |  |  |  |  |  |  |  | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | ---
Mar. 14, 2016 USD ($) | Jul. 08, 2015 USD ($) | Nov. 03, 2014 USD ($) | Jul. 31, 2014 USD ($) | Jul. 02, 2014 USD ($) | Apr. 30, 2014 USD ($) | Jul. 22, 2013 USD ($) | Jun. 30, 2016 USD ($) | Jun. 30, 2015 USD ($) | Jun. 30, 2014 USD ($) | Jun. 30, 2013 USD ($)
Zephyrus [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles | $ 7,400,000 |  |  |  |  |  |  |  |  |  |
Zephyrus [Member] | Instruments Sales Contingency [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | $ 3,500,000 |  |  |  |  |  |  | $ 3,500,000 |  |  |
Business Combination, Contingent Consideration, Liability, Number of Instruments Sold | 10 |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Anniversary of Closing Date | 3 years |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Cumulative Sales | $ 3,000,000 |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability, Number of Years Within Closing Date | 4 years 182 days |  |  |  |  |  |  |  |  |  |
Zephyrus [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Gross | $ 8,000,000 |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High | 7,000,000 |  |  |  |  |  |  |  |  |  |
Business Combination, Contingent Consideration, Liability | $ 3,500,000 |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | 8,030,000 |  |  |
Cliniqa [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 18,000,000 |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  | 14 years |  |  |  |  |  |  |  |  |
Cliniqa [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 27,000,000 |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  | 13 years |  |  |  |  |  |  |  |  |
Cliniqa [Member] | Trademarks and Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  | $ 1,100,000 |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  | 4 years |  |  |  |  |  |  |  |  |
Cliniqa [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  | $ 83,000,000 |  |  |  |  |  | 82,888,000 |  |  |
CyVek, Inc. [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | $ 20,200,000 |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  | 15 years |  |  |  |  |  |  |  |
CyVek, Inc. [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | $ 100,000 |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  | 1 year 182 days |  |  |  |  |  |  |  |
CyVek, Inc. [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  | $ 600,000 |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  | 10 years |  |  |  |  |  |  |  |
CyVek, Inc. [Member] | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Acquisition Related Costs |  |  |  |  |  |  |  |  | $ 100,000 |  |
CyVek, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Gross |  |  | $ 62,000,000 |  |  |  |  |  | 62,000,000 |  |
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |  |  |  |  |  |  |  |  | 35,000,000 |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | 59,927,000 |  |  |
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures |  |  | $ 10,000,000 |  |  |  |  |  |  |  |
Noncontrolling Interest, Ownership Percentage by Parent |  |  | 19.90% |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability |  |  | $ 35,000,000 |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contingent Liability, Percentage |  |  | 50.00% |  |  |  |  |  |  |  |
Business Combination, Milestone Payment Threshold |  |  | $ 100,000,000 |  |  |  |  |  |  |  |
Business Combination, Liabilities Arising from Contingencies, Amount Recognized |  |  |  |  |  |  |  |  | 35,000,000 |  |
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain |  |  | $ 8,300,000 |  |  |  |  |  |  |  |
ProteinSimple [Member] | Developed Technology Rights [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 9 years |  |  |  |  |  |  |
ProteinSimple [Member] | Developed Technology Rights [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 10 years |  |  |  |  |  |  |
ProteinSimple [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  | $ 39,200,000 |  |  |  |  |  |  |
ProteinSimple [Member] | Trade Names [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 18 years |  |  |  |  |  |  |
ProteinSimple [Member] | Trade Names [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 20 years |  |  |  |  |  |  |
ProteinSimple [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  | $ 36,100,000 |  |  |  |  |  |  |
ProteinSimple [Member] | Customer Relationships [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 14 years |  |  |  |  |  |  |
ProteinSimple [Member] | Customer Relationships [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 16 years |  |  |  |  |  |  |
ProteinSimple [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  | $ 101,600,000 |  |  |  |  |  |  |
ProteinSimple [Member] | Noncompete Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  | $ 200,000 |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  | 3 years |  |  |  |  |  |  |
ProteinSimple [Member] | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Acquisition Related Costs |  |  |  |  |  |  |  | 800,000 |  |  |
ProteinSimple [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | 300,053,000 |  |  |
Novus Holdings, LLC [Member] | Developed Technology Rights [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 4 years |  |  |  |  |  |
Novus Holdings, LLC [Member] | Developed Technology Rights [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 12 years |  |  |  |  |  |
Novus Holdings, LLC [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  | $ 5,000,000 |  |  |  |  |  |
Novus Holdings, LLC [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  | $ 5,300,000 |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 20 years |  |  |  |  |  |
Novus Holdings, LLC [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  | $ 14,400,000 |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  | 15 years |  |  |  |  |  |
Novus Holdings, LLC [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | 60,122,000 |  |  |
Business Combination, Acquisition Related Costs |  |  |  |  | $ 100,000 |  |  |  |  |  |
PrimeGene [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  | $ 2,200,000 |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 9 years |  |  |  |  |
PrimeGene [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  | $ 3,000,000 |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 11 years |  |  |  |  |
PrimeGene [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  | $ 9,100,000 |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 9 years |  |  |  |  |
PrimeGene [Member] | Noncompete Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  | $ 300,000 |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  | 3 years |  |  |  |  |
PrimeGene [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Gross |  |  |  |  |  |  |  |  |  | $ 6,000,000 |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  | $ 6,000,000 |  | 6,031,000 |  |  |
Business Combination, Acquisition Related Costs |  |  |  |  |  | $ 400,000 |  |  |  |  |
Bionostics [Member] | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  |  | $ 14,400,000 |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  | 9 years |  |  |  |
Bionostics [Member] | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  |  | $ 2,700,000 |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  | 5 years |  |  |  |
Bionostics [Member] | Customer Relationships [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  |  | $ 41,000,000 |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  | 14 years |  |  |  |
Bionostics [Member] | Noncompete Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles |  |  |  |  |  |  | $ 2,400,000 |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  | 3 years |  |  |  |
Bionostics [Member] | Selling, General and Administrative Expenses [Member] |  |  |  |  |  |  |  |  |  |  |
Business Combination, Acquisition Related Costs |  |  |  |  |  |  |  |  |  | 500,000 | $ 600,000
Bionostics [Member] |  |  |  |  |  |  |  |  |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | $ 103,149,000 |  |  |
Developed Technology Rights [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 8 years |  |  |
Developed Technology Rights [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 15 years |  |  |
Trade Names [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 5 years |  |  |
Trade Names [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 16 years |  |  |
Customer Relationships [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 8 years |  |  |
Customer Relationships [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 16 years |  |  |
Noncompete Agreements [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 3 years |  |  |
Noncompete Agreements [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life |  |  |  |  |  |  |  | 5 years |  |  |
Payments to Acquire Businesses, Net of Cash Acquired |  |  |  |  |  |  |  | $ 91,423,000 | 420,102,000 | 109,180,000 |
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain |  |  |  |  |  |  |  | $ 0 | $ 8,300,000 | $ 0 |

X
- Definition Represents the number of years of the anniversary of the closing date from contingent consideration in a business combination. + References No definition available. + Details
Name: | tech_BusinessCombinationContingentConsiderationLiabilityAnniversaryOfClosingDate
Namespace Prefix: | tech_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the cumulative sales generated from contingent consideration in a business combination. + References No definition available. + Details
Name: | tech_BusinessCombinationContingentConsiderationLiabilityCumulativeSales
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of instruments sold from contingent consideration in a business combination. + References No definition available. + Details
Name: | tech_BusinessCombinationContingentConsiderationLiabilityNumberOfInstrumentsSold
Namespace Prefix: | tech_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of years within the closing date from contingent consideration in a business combination. + References No definition available. + Details
Name: | tech_BusinessCombinationContingentConsiderationLiabilityNumberOfYearsWithinClosingDate
Namespace Prefix: | tech_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The threshold for the milestone payment the company is liable for if the subsidiaries exceeds an specific amount of revenue. + References No definition available. + Details
Name: | tech_BusinessCombinationMilestonePaymentThreshold
Namespace Prefix: | tech_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of a milestone payment that is contingent on the revenues generated by the subsidiary. + References No definition available. + Details
Name: | tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiabilityPercentage
Namespace Prefix: | tech_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=73531572&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (d)(1) -URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of liability arising from an inherited contingency (as defined) which has been recognized as of the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of identifiable intangible assets recognized as of the acquisition date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -URI http://asc.fasb.org/extlink&oid=73531372&loc=d3e2207-128464 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g)(2) -URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.12) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The parent entity's interest in net assets of the subsidiary, expressed as a percentage. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByParent
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_ZephyrusMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=tech_InstrumentsSalesContingencyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_CliniqaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_CyvekIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_ProteinSimpleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_NoncompeteAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_NovusHoldingsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_PrimeGeneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=tech_BionosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |